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THE EFFECT OF DONOR AGE ON ENGINEERED TENDON TISSUE
DERIVED FROM TENOCYTES AND MESENCHYMAL STEM CELLS
A.J. Turlo y, Y. Ashraf Kharaz z, P.D. Clegg z, J. Anderson z, M.J. Peffers z.
yWarsaw Univ. of Life Sci., Warsaw, Poland; zUniv. of Liverpool,
Liverpool, United Kingdom
Purpose: To compare age-related changes in the proteome of tendon
tissue-engineered constructs (TEC) derived from mesenchymal stem
cells (MSCs) and tenocytes.
Methods: Liquid chromatography tandemmass spectrometry was used
to assess the whole proteome of TEC derived fromyoung (n¼ 7) and old
(n¼ 6) equine tenocytes or human MSCs (equal sample sizes, n¼ 4).
Label-free (LF) quantiﬁcation was undertaken to identify proteins dif-
ferentially expressed (DE) between the age groups. Structural, func-
tional and protein network analysis of the data was performed using
Ingenuity Pathway Analysis (IPA), Matrisome DB and the Search Tool for
Retrieval of Interacting Genes/Proteins (STRING) for tenocyte and MSC
TEC separately. Neopeptide identiﬁcation was performed to determine
extracellular matrix (ECM) fragmentation patterns. Immunohis-
tochemistry and biochemical analysis were also undertaken.
Results: 205 proteins were considered DE in MSC and 41 in tenocyte-
derived TEC. LF quantiﬁcation demonstrated a higher number of ECM
protein, nuclear proteins, and a lower number of cytoplasmatic and
plasma membrane proteins in the tenocyte TEC in comparison to MSC
TEC. For both cell types ageing was associated with increased abun-
dance of cytoskeletal proteins, including actin-binding molecule cal-
ponin 1, considered to be responsible for cell mechanoresponsiveness.
Calponin 1 was among the most abundant DE protein determined by
proteomic analysis and was conﬁrmed using immunohistochemistry in
old MSC and tenocyte TEC. Increased number of neopeptides for col-
lagenous protein was identiﬁed in old TEC derived from both types of
cells, suggesting enhanced collagen turnover in ECM. Gene ontology
terms determined for proteins DE in old MSC TEC were related to
increased cell antioxidant response (FDR< 0.001) , whilst in tenocyte
TEC to accumulation of collagen breakdown products (FDR< 0.001).
Increased total collagen content in old TEC was conﬁrmed using a
hydroxyproline assay. Transforming growth factor beta-1 was proposed
as potential upstream regulator of age-related changes in ECM com-
position of tenocyte and MSC-derived TEC.
Conclusions: Ageing affects synthetic activity of cells used for gen-
eration of tendon TEC, which is reﬂected by alterations in their protein
content. Proteomic proﬁle of ageing in tendon TECs differs between
MSC and tenocyte-derived constructs. Age-related changes in TEC
protein composition may affect their functionality and should be taken
into consideration in applying autologous cell therapies in elderly
patients.
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TARGETING CARTILAGE AGING AS OSTEOARTHRITIS THERAPEUTICS
BY DRUG REPURPOSING
U. Nogueira-Recalde y, E. Dominguez z, M.I. Loza z, F.J. Blanco y,
B. Carames y. yGrupo de Biología del Cartílago, Division de Reumatología,
INIBIC, A Coru~na, Spain; zBiofarma Res. Group, Univ. de Santiago de
Compostela, Santiago de Compostela, Spain
Purpose: Effective treatments for Osteoarthritis (OA) are not available.
In aging-related diseases, including OA, failure of cellular homeostasis
mechanisms, such as autophagy can cause extracellular matrix
destruction and cell death. Chondrocytes are essential for the main-
tenance of cartilage integrity. With aging, chondrocyte function is
diminished, contributing to a cellular senescence phenotype often
observed in OA chondrocytes. In addition, a defect in autophagy is
observed in both aging and cartilage degeneration. The objective of this
study was to identify anti-senescence and pro-autophagy molecules by a
cell-based high-throughput screening (HTS) in human chondrocytes.
Methods: To induce cellular senescence or reduced autophagy,
immortalized human chondrocytes (TC28a2) were seeded (2500 cells/
well) in 384 well plates, and treated with IL-6 (20 ng/ml) for 72 or 18
hours, respectively. Then, chondrocytes were incubated with Prestwick
Chemical Library (1120 approved drugs with chemical and pharmaco-
logical diversity, as well as bioavailability and safety in humans) at
10 mM for 72 hours. To identify anti-senescence hits, nuclei was stained
with Hoechst 33342 (2,5mg/ml), while b-galactosidase subcellular
structures was stained by using Imagene Green C12FDG substrate(30 mM). To evaluate autophagic ﬂux, a reporter cell line was generated
by retrovirus transfection of pBABE-mCherry-EGFP-LC3 plasmid in
TC28a2 chondrocytes. Plates were imaged by using Operetta® High
Content Screening (HCS) system in non-confocal mode using the 20x
WD objective. For each well, 4 ﬁelds and 4 planes of bright ﬁeld,
Hoechst and ﬂuorescein channels were obtained. Relative intensity of
C12FDG in cytoplasm and number of autophagosomes/autolysosomes
per area of cytoplasm were determined to quantitate b-galactosidase
activity and autophagy ﬂux respectively. Compound validation was
performed in TC28a2 chondrocytes and in primary human chon-
drocytes by evaluating cell senescence, autophagy pathway and cell
death by apoptosis.
Results: A primary screening was performed to identify anti-sen-
escence compounds by measurement of senescence-associated b-
galactosidase activity. 308 compounds with anti-senescence effects
were identiﬁed. The anti-senescence hits were analyzed by mon-
itorizing autophagic ﬂux. 42 compounds with both anti-senescence
and pro-autophagy effects were selected. Then, one compound was
selected for further validation. The compound reduced chondrocyte
senescence, increased autophagy (p < 0.0001) and protected against
cell death by apoptosis in human chondrocytes (p < 0.05) in
response to IL-6. Interestingly, this protective effect was partially
mediated by mTOR inhibition, a proposed mechanism to prevent
cartilage aging.
Conclusions: Our screening methodology provides a unique oppor-
tunity to repurpose drugs and mechanisms to prevent cartilage aging.
Autophagy activation and protection against senescence in chon-
drocytes may provide beneﬁts for delaying cartilage degeneration.
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STRAIN-DEPENDENT DIFFERENCES IN AGE-ASSOCIATED
OSTEOARTHRITIS PATHOGENESIS
A. Ratneswaran y, B.A. Russell y, S. Benipal y, G.A. Erickson y, F. Beier y,z.
yWestern Univ., London, ON, Canada; zChildren's Hlth.Res. Inst., London,
ON, Canada
Purpose: Osteoarthritis (OA) is a progressive disabling disorder
affecting the entire joint. In order to elucidate molecular mechanisms
and assess interventions, many laboratories use animal models to
recapitulate disease progression. The majority of rodent studies of OA
employ surgical models to induce a post-traumatic disease phenotype.
However, post-traumatic OA only affects a subset of patients, and these
results may not be generalized to other types of OA. Similarly, many
groups use C57/B6 mice for transgenic studies, and CD1 mice for wild-
type in-vivo or ex-vivo studies; yet the spontaneous progression of OA
in CD1 mice has not been evaluated. Our ﬁrst aim was to compare
aging models of wild type CD1 and C57/B6 mice to examine whether
there are strain-speciﬁc differences that could affect the progression of
OA. In addition, we previously showed that cartilage-speciﬁc inacti-
vation of the nuclear receptor PPARdelta results in signiﬁcantly
decreased severity of OA in a model of post-traumatic OA in mice.
Our second objective was to assess whether cartilage-speciﬁc knock-
out of PPARdelta is protective in an aging model of OA (in a C57/B6
background).
Methods: CD1, C57/B6, and cartilage-speciﬁc PPARdelta knockout
mice were aged to 12 months, 20 months, or 24 months, and then
subjected to gait analysis. End point blood glucose and liver weight
were measured. Knees, elbows, and ankles were harvested for histol-
ogy. Mice were compared through classical measures of OA pro-
gression including Toluidine-blue staining with OARSI scoring,
immunohistochemistry for cartilage matrix breakdown products,
picrosirius red staining for collagen structure and organization, as well
as quantitative measures of cartilage and synovial thickness. Synovium
was scored based on degree of hyperplasia and inﬁltration of inﬂam-
matory cells, and bone changes were assessed through H&E and TRAP
staining for osteoclasts.
Results: CD1 mice at 1 year of age present with early OA-like changes
to the knee joint synovium and subchondral bone, including thicken-
ing of both tissues, but otherwise healthy joints. At 20 months of age
CD1 mice have severe OA in the medial compartment of the knee
affecting all joint tissues, including cartilage degeneration, marrow
changes and subchondral bone thickening, and synovial hyperplasia.
This is further exacerbated at 2 years of age, and is more severe in male
mice than female mice at all time points. Conversely, C57/B6 mice
present with only minor changes in articular cartilage at 2 years,
